Ausbiz Capital is now SureStone Capital. Same team, same ABN and AFS authorisations.

Health Care ASX Announcements

Plain-English summaries of selected price-sensitive ASX announcements in the Health Care sector. Every summary is drawn only from the company's official release.

November 2026

Imricor Medical Systems, Inc. (ASX:IMR)
QuarterlyPrice Sensitive

Imricor Starts U.S. Sales, Quarterly Revenue Up 437%

Imricor began U.S. commercial sales of NorthStar to two children's hospitals, lifting quarterly revenue 437% to US$188k, and held US$62.1m cash at 30 September.

Imricor Medical Systems, Inc. (ASX:IMR)

8:53 am

13 Nov 2026

Artrya Limited (ASX:AYA)
OperationsPrice Sensitive

Artrya Signs Five-Year HonorHealth Deal, US$0.5m Minimum

Artrya signed a five-year agreement with Arizona's HonorHealth, its fifth U.S. customer, with a US$0.5 million minimum value and unquantified per-scan upside.

Artrya Limited (ASX:AYA)

8:50 am

13 Nov 2026

Mayne Pharma Group Limited (ASX:MYX)
OperationsPrice Sensitive

Mayne Pharma to Sell International Segment for $55.5m

Mayne Pharma has agreed to sell Mayne Pharma International to Evaris Pharma for $55.5 million cash, subject to ACCC approval, to focus on the United States.

Mayne Pharma Group Limited (ASX:MYX)

8:52 am

6 Nov 2026

AVITA Medical, Inc. (ASX:AVH)
GuidancePrice Sensitive

AVITA Medical Raises 2026 Revenue Guidance to $92m-$94m

AVITA Medical's Q3 revenue rose 53% to approximately $26.1 million, and the company raised its full-year 2026 revenue guidance to $92 million to $94 million.

AVITA Medical, Inc. (ASX:AVH)

8:26 am

6 Nov 2026

Pacific Edge Limited (ASX:PEB)
OperationsPrice Sensitive

Pacific Edge Wins Medicare Coverage for Cxbladder Triage

Pacific Edge says the final Medicare LCD covers Cxbladder Triage and Triage Plus for intermediate risk microhematuria patients, effective 20 December 2026.

Pacific Edge Limited (ASX:PEB)

7:30 am

6 Nov 2026

Island Pharmaceuticals Limited (ASX:ILA)
ClinicalPrice Sensitive

Island Pharma Starts Primate Surgeries for Marburg Study

Island Pharma has begun surgeries on 22 non-human primates at USAMRIID ahead of its Galidesivir Marburg dose study, with dosing expected in early December.

Island Pharmaceuticals Limited (ASX:ILA)

9:30 am

4 Nov 2026

Orthocell Limited (ASX:OCC)
ClinicalPrice Sensitive

Orthocell Partner Gets FDA 510(k) Clearance for PearlBone

Orthocell says Marine Biomedical, in which it holds 12%, received FDA 510(k) clearance for PearlBone. Orthocell holds a first right of refusal on distribution.

Orthocell Limited (ASX:OCC)

10:09 am

3 Nov 2026

October 2026

Resmed Inc. (ASX:RMD)
QuarterlyPrice Sensitive

Resmed Q1 Fiscal 2027 Revenue Up 6%, Non-GAAP EPS Up 14%

Resmed reported Q1 fiscal 2027 revenue of US$1,415 million, up 6%, and non-GAAP diluted EPS of US$2.91, up 14%, and held its FY 2027 guidance unchanged.

Resmed Inc. (ASX:RMD)

8:12 am

30 Oct 2026

Alcidion Group Limited (ASX:ALC)
ResultsPrice Sensitive

Alcidion FY27 Contracted Revenue $50.0M, Up 38%

Alcidion's FY27 contracted revenue was $50.0M at 30 September 2026, up 38% on pcp, and it reconfirmed guidance for revenue and Underlying EBITDA to exceed FY26.

Alcidion Group Limited (ASX:ALC)

8:20 am

29 Oct 2026

Clarity Pharmaceuticals Ltd (ASX:CU6)
ClinicalPrice Sensitive

Clarity Doses 383-Participant Target in Phase III CLARIFY

Clarity's Phase III CLARIFY trial of 64Cu-SAR-bisPSMA has dosed its target of 383 participants, with topline data anticipated in the first half of 2027.

Clarity Pharmaceuticals Ltd (ASX:CU6)

9:14 am

27 Oct 2026

Mayne Pharma Group Limited (ASX:MYX)
ResultsPrice Sensitive

Mayne Pharma 1Q FY27 Underlying EBITDA Falls to $5.3M

Mayne Pharma reported unaudited 1Q FY27 revenue of $95.7 million and underlying EBITDA of $5.3 million, down 52%, as Dermatology sales fell on generic entry.

Mayne Pharma Group Limited (ASX:MYX)

8:49 am

26 Oct 2026

Cochlear Limited (ASX:COH)
GuidancePrice Sensitive

Cochlear Holds FY27 Profit Guidance of $330M to $350M

Cochlear reaffirmed FY27 underlying net profit guidance of $330 million to $350 million at its 2026 AGM, after FY26 underlying net profit of $322 million.

Cochlear Limited (ASX:COH)

8:33 am

26 Oct 2026

Copyright © 2026 SureStone Capital